Matches in SemOpenAlex for { <https://semopenalex.org/work/W135730891> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W135730891 endingPage "66" @default.
- W135730891 startingPage "357" @default.
- W135730891 abstract "The UpGrade study evaluated the safety profile and effectiveness of insulin aspart (IAsp, NovoRapid®) and soluble human insulin (SHI) in patients with Type 2 diabetes mellitus, under current clinical practice conditions.This 26-week, open-label, non-randomized, observational safety study recruited patients using insulin ± metformin and having received ≥ 2 injections of IAsp or SHI over a period of 3 months to 3 years. Data were collected via patient recall and treatment diaries, at baseline, 13- and 26-week visits. The number of major hypoglycemic episodes was the primary endpoint. Secondary endpoints were minor hypoglycemic episodes, HbA1c, fasting and post-prandial blood glucose.Overall, 4099 patients were included. At study end the incidence of major hypoglycemia was low (mean rate 0.117 ev/pt-y) and rates were lower in subjects using IAsp compared with those using SHI, for both major (0.115 vs. 0.121) and minor (6.648 vs. 9.530) episodes. IAsp correlated with a significantly lower risk of minor hypoglycemic episodes (IRR=0.64, P<0.0001). Overall, HbA1c levels decreased across 26 weeks (7.97% to 7.63%, P<0.0001); IAsp had greater HbA1c reduction than SHI (-0.39% and -0.22%, respectively) and was associated with a marginally significant likelihood (vs. SHI) of achieving HbA1c reduction of ≥ 0.5% (OR=1.22, P=0.059).Under current clinical practice conditions, treatment of patients with Type 2 diabetes mellitus using either IAsp or SHI resulted in low rates of major hypoglycemia after 26 weeks. Patients using IAsp had a better clinical safety profile and a greater reduction in HbA1c compared with patients using SHI." @default.
- W135730891 created "2016-06-24" @default.
- W135730891 creator A5005444334 @default.
- W135730891 creator A5020172547 @default.
- W135730891 creator A5021260877 @default.
- W135730891 creator A5040809526 @default.
- W135730891 creator A5043892665 @default.
- W135730891 creator A5073189290 @default.
- W135730891 creator A5077574989 @default.
- W135730891 date "2012-12-01" @default.
- W135730891 modified "2023-10-15" @default.
- W135730891 title "Safety and efficacy of insulin aspart and soluble human insulin in Type 2 diabetes mellitus." @default.
- W135730891 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23235191" @default.
- W135730891 hasPublicationYear "2012" @default.
- W135730891 type Work @default.
- W135730891 sameAs 135730891 @default.
- W135730891 citedByCount "3" @default.
- W135730891 countsByYear W1357308912015 @default.
- W135730891 countsByYear W1357308912022 @default.
- W135730891 crossrefType "journal-article" @default.
- W135730891 hasAuthorship W135730891A5005444334 @default.
- W135730891 hasAuthorship W135730891A5020172547 @default.
- W135730891 hasAuthorship W135730891A5021260877 @default.
- W135730891 hasAuthorship W135730891A5040809526 @default.
- W135730891 hasAuthorship W135730891A5043892665 @default.
- W135730891 hasAuthorship W135730891A5073189290 @default.
- W135730891 hasAuthorship W135730891A5077574989 @default.
- W135730891 hasConcept C126322002 @default.
- W135730891 hasConcept C134018914 @default.
- W135730891 hasConcept C168563851 @default.
- W135730891 hasConcept C203092338 @default.
- W135730891 hasConcept C2777180221 @default.
- W135730891 hasConcept C2779306644 @default.
- W135730891 hasConcept C2779908123 @default.
- W135730891 hasConcept C2780323712 @default.
- W135730891 hasConcept C2780668416 @default.
- W135730891 hasConcept C2910068830 @default.
- W135730891 hasConcept C555293320 @default.
- W135730891 hasConcept C71924100 @default.
- W135730891 hasConcept C90924648 @default.
- W135730891 hasConceptScore W135730891C126322002 @default.
- W135730891 hasConceptScore W135730891C134018914 @default.
- W135730891 hasConceptScore W135730891C168563851 @default.
- W135730891 hasConceptScore W135730891C203092338 @default.
- W135730891 hasConceptScore W135730891C2777180221 @default.
- W135730891 hasConceptScore W135730891C2779306644 @default.
- W135730891 hasConceptScore W135730891C2779908123 @default.
- W135730891 hasConceptScore W135730891C2780323712 @default.
- W135730891 hasConceptScore W135730891C2780668416 @default.
- W135730891 hasConceptScore W135730891C2910068830 @default.
- W135730891 hasConceptScore W135730891C555293320 @default.
- W135730891 hasConceptScore W135730891C71924100 @default.
- W135730891 hasConceptScore W135730891C90924648 @default.
- W135730891 hasIssue "4" @default.
- W135730891 hasLocation W1357308911 @default.
- W135730891 hasOpenAccess W135730891 @default.
- W135730891 hasPrimaryLocation W1357308911 @default.
- W135730891 hasRelatedWork W1996010611 @default.
- W135730891 hasRelatedWork W2045993936 @default.
- W135730891 hasRelatedWork W2053519879 @default.
- W135730891 hasRelatedWork W2057262151 @default.
- W135730891 hasRelatedWork W2057434408 @default.
- W135730891 hasRelatedWork W2076754594 @default.
- W135730891 hasRelatedWork W2083753940 @default.
- W135730891 hasRelatedWork W2110641431 @default.
- W135730891 hasRelatedWork W2121663374 @default.
- W135730891 hasRelatedWork W2271534741 @default.
- W135730891 hasVolume "37" @default.
- W135730891 isParatext "false" @default.
- W135730891 isRetracted "false" @default.
- W135730891 magId "135730891" @default.
- W135730891 workType "article" @default.